KR102645633B1 - 신경학적 장애를 치료하는 방법 - Google Patents

신경학적 장애를 치료하는 방법 Download PDF

Info

Publication number
KR102645633B1
KR102645633B1 KR1020227033161A KR20227033161A KR102645633B1 KR 102645633 B1 KR102645633 B1 KR 102645633B1 KR 1020227033161 A KR1020227033161 A KR 1020227033161A KR 20227033161 A KR20227033161 A KR 20227033161A KR 102645633 B1 KR102645633 B1 KR 102645633B1
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical composition
apoe4
disease
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227033161A
Other languages
English (en)
Korean (ko)
Other versions
KR20220136476A (ko
Inventor
마틴 톨라
존 헤이
페트르 코시스
제레미 유
Original Assignee
알제온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102645633(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알제온, 인크. filed Critical 알제온, 인크.
Publication of KR20220136476A publication Critical patent/KR20220136476A/ko
Application granted granted Critical
Publication of KR102645633B1 publication Critical patent/KR102645633B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
KR1020227033161A 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법 Active KR102645633B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461968595P 2014-03-21 2014-03-21
US61/968,595 2014-03-21
PCT/US2015/022058 WO2015143447A2 (en) 2014-03-21 2015-03-23 Methods for treating neurological disorders
KR1020167027090A KR102448386B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027090A Division KR102448386B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20220136476A KR20220136476A (ko) 2022-10-07
KR102645633B1 true KR102645633B1 (ko) 2024-03-11

Family

ID=54145492

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227033161A Active KR102645633B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법
KR1020167027090A Active KR102448386B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167027090A Active KR102448386B1 (ko) 2014-03-21 2015-03-23 신경학적 장애를 치료하는 방법

Country Status (19)

Country Link
US (3) US10471029B2 (enExample)
EP (2) EP4289820A3 (enExample)
JP (5) JP6588962B2 (enExample)
KR (2) KR102645633B1 (enExample)
CN (1) CN106170563A (enExample)
AU (1) AU2015230972B2 (enExample)
CA (1) CA2941415A1 (enExample)
DK (1) DK3119911T3 (enExample)
ES (1) ES2960625T3 (enExample)
FI (1) FI3119911T3 (enExample)
HR (1) HRP20231172T1 (enExample)
HU (1) HUE063369T2 (enExample)
LT (1) LT3119911T (enExample)
PL (1) PL3119911T3 (enExample)
PT (1) PT3119911T (enExample)
RS (1) RS64744B1 (enExample)
SI (1) SI3119911T1 (enExample)
SM (1) SMT202300369T1 (enExample)
WO (1) WO2015143447A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
EP3485892B1 (en) * 2016-07-13 2021-10-13 Mitos Co., Ltd. Composition for prevention or treatment of mild cognitive impairment or dementia containing hydrogen as active ingredient
CN108623501B (zh) * 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN110668980A (zh) * 2018-07-03 2020-01-10 浙江京新药业股份有限公司 一种2-取代的高牛磺酸衍生物
US12285400B2 (en) * 2018-08-01 2025-04-29 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CA3144008A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
EP4514335A1 (en) 2022-04-28 2025-03-05 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
KR20250110352A (ko) 2022-12-02 2025-07-18 알제온, 인크. 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
CN1867795B (zh) 2003-08-11 2010-12-08 加州理工学院 微流体的大规模集成
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
WO2012006329A2 (en) * 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
AU2014262890B2 (en) 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
JP6789579B2 (ja) 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
US20180250249A1 (en) 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caltagirone et al., "The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.", Aging clinical and experimental research v.24 no.6 , pp.580 - 587, 2012. 1부.*

Also Published As

Publication number Publication date
WO2015143447A2 (en) 2015-09-24
EP4289820A2 (en) 2023-12-13
ES2960625T3 (es) 2024-03-05
EP3119911A2 (en) 2017-01-25
JP2019065044A (ja) 2019-04-25
LT3119911T (lt) 2023-10-10
JP2022159555A (ja) 2022-10-17
JP2017511377A (ja) 2017-04-20
HRP20231172T1 (hr) 2024-01-05
JP2020109123A (ja) 2020-07-16
CN106170563A (zh) 2016-11-30
EP4289820A3 (en) 2024-03-13
SMT202300369T1 (it) 2023-11-13
KR20220136476A (ko) 2022-10-07
US20170172952A1 (en) 2017-06-22
PT3119911T (pt) 2023-11-03
WO2015143447A3 (en) 2016-01-14
FI3119911T3 (fi) 2023-09-27
JP6588962B2 (ja) 2019-10-09
US20200101031A1 (en) 2020-04-02
US10471029B2 (en) 2019-11-12
KR102448386B1 (ko) 2022-09-28
DK3119911T3 (da) 2023-10-30
RS64744B1 (sr) 2023-11-30
HUE063369T2 (hu) 2024-01-28
PL3119911T3 (pl) 2024-01-22
AU2015230972A1 (en) 2016-09-15
EP3119911A4 (en) 2017-12-13
US20230087041A1 (en) 2023-03-23
CA2941415A1 (en) 2015-09-24
AU2015230972B2 (en) 2021-05-27
SI3119911T1 (sl) 2023-12-29
KR20160128391A (ko) 2016-11-07
EP3119911B1 (en) 2023-08-09
JP2025022992A (ja) 2025-02-14

Similar Documents

Publication Publication Date Title
KR102645633B1 (ko) 신경학적 장애를 치료하는 방법
KR102664288B1 (ko) 카파 오피오이드 수용체 효능제의 경구 제형
TWI633887B (zh) 用於預防及／或治療多囊性腎臟病之藥物
US20070190043A1 (en) Use of a topical medicament comprising riluzole
JP2009537565A (ja) Ｒ（＋）およびｓ（−）プラミペキソール組成とそれを利用する方法
KR20120060203A (ko) 신규한 오피오이드의 카바메이트 아미노산과 펩티드 프로드럭 및 그의 용도
US10870678B2 (en) Chiral peptides
JP2016521249A (ja) リナクロチド組成物
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
AU2014331704A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20240423995A1 (en) C-kit inhibitors and uses for treating and preventing inflammatory conditions
CN119371651B (zh) 一种靶向Bcr-Abl的自组装纳米材料的制备方法及其用途
CN115103675B (zh) 用于治疗和预防中枢神经系统疾病的化合物
RU2835627C2 (ru) Составы для перорального применения агонистов каппа-опиоидного рецептора
HK40048981B (zh) κ阿片受体激动剂的口服配制品
JP2007261979A (ja) カルプロニウムを含有する疲労回復用医薬組成物
EA040600B1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
AU2008200878A1 (en) Use of a topical medicament comprising riluzole

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220923

Application number text: 1020167027090

Filing date: 20160929

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230317

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231208

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240305

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240306

End annual number: 3

Start annual number: 1

PG1601 Publication of registration